MT expression in tumors is associated with cancer treatment resistance (Si and Lang, 2018) and targeting MT proteins has been suggested to be a powerful tool to boost response rates to metal-based therapies (Borchert et al., 2020). This evidence concerns the gene MCAT and cancer.